This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer

Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering an agent selected from i) an effective amount of an anti-estrogen agent

The present invention relates to the characterization and production of trastuzumab. The present disclosure provides in part methods for evaluating identifying and/or producing (e.g. manufacturing) trastuzumab. In some instances methods herein allow highly resolved evaluation of trastuzumab useful for inter alia manufacturing trastuzumab characterizing trastuzumab identifying and/or confirming trastuzumab monitoring the structure of trastuzumab comparing trastuzumab preparations made over time o...

Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant 5 tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by coadministering an agent selected from i) an effective amount of an anti-estrogen agent

This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivat...

Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering either i) an effective amount of an anti-estrogen agent or ii) an effective amount of a receptor tyrosine kinase inhibitor and an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody, and optionally an effective amount trastuzumab. Also disclosed is a bispecific anti-ErbB2/anti-Erb...

A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer containing trastuzumab temsirolimus and/or HKI-272 optionally in combination with other anti-neoplastic agents or immune modulators are described.

The present invention relates to combination therapy with paclitaxel trastuzumab-MCC-DM1 and optionally pertuzumab.

The invention relates to a novel breast cancer cell line that is positive for the HER2 marker, which has developed induced resistance to the drugs lapatinib and trastuzumab, characterised in that the EGFR, HER2 and HER4 receptors are hyperphosphorylated. Said cell line can be used in screening methods for identifying new anti-carcinogenic compounds which can be used to treat resistant breast cancer.

P-74233-PC [000327] This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of: a) treating a subject suffering from breast cancer